Form 4 for DRIO DarioHealth Corp.

Accepted 2021-11-05 00:00:00 ET · period of report 2021-11-03 · accession 0001104659-21-135188 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
M	2021-11-05	2021-11-03+	DRIO	Raphael Erez	CEO, Dir	S - Sale	$18.86	-38.3K	847.1K	-4%	-$723.2K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2021-11-04	S	D	7,857	$18.49	839,259	D	—	—	(F1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2021. (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.02 to $19.10, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3).
2	Common	Common Stock	2021-11-03	S	D	30,483	$18.96	847,116	D	—	—	(F1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2021. (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.40 to $19.38, inclusive. The Reporting Person undertakes to provide to DarioHealth Corp. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2).